URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers

The clinical benefit of tyrosine kinase inhibitors (TKIs)-based systemic therapy for advanced hepatocellular carcinoma (HCC) is limited due to drug resistance. Here, we uncover that lipid metabolism reprogramming mediated by unconventional prefoldin RPB5 interactor (URI) endows HCC with resistance t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Zhiwen, Pan, Yufei, Shang, Taiyu, Jiang, Tianyi, Lin, Yunkai, Yang, Chun, Pang, Shujie, Cui, Xiaowen, Wang, Yixiu, Feng, Xiao fan, Xu, Mengyou, Pei, Mengmiao, Chen, Yibin, Li, Xin, Ding, Jin, Tan, Yexiong, Wang, Hongyang, Dong, Liwei, Wang, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560259/
https://www.ncbi.nlm.nih.gov/pubmed/37805657
http://dx.doi.org/10.1038/s41467-023-41852-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560259/
https://www.ncbi.nlm.nih.gov/pubmed/37805657
http://dx.doi.org/10.1038/s41467-023-41852-z

Ejemplares similares